37 results on '"Uceda Renteria, Sara Colonia"'
Search Results
2. Impact of SARS-CoV-2 Omicron and Delta variants in patients requiring intensive care unit (ICU) admission for COVID-19, Northern Italy, December 2021 to January 2022
3. On the lookout for influenza viruses in Italy during the 2021-2022 season: Along came A(H3N2) viruses with a new phylogenetic makeup of their hemagglutinin
4. Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension
5. Chromosome 3 cluster rs11385942 variant links complement activation with severe COVID-19
6. Complement activation and endothelial perturbation parallel COVID-19 severity and activity
7. Increased circulation of echovirus 11 in the general population and hospital patients as elicited by the non-polio enterovirus laboratory-based sentinel surveillance in northern Italy, 2023
8. Significant improvement of non-invasive fibrosis tests in HDV compensated cirrhotic patients with clinically significant portal hypertension treated with BLV monotherapy un to 96 weeks
9. Quantification of serum HDV RNA in untreated and Bulevirtide-treated patients with CHD: a comparison between Robogene 2.0 and Eurobioplex
10. Kinetics of hepatitis B core related antigen in patients with compensated HDV cirrhosis treated with Bulevirtide monotherapy for 72 weeks: a single-center study
11. Pretreatment and on-therapy HDV RNA levels predict response to Bulevirtide monotherapy in HDV compensated cirrhotic patients treated up to 96 weeks
12. Epidemiologic and Molecular Study of EVs in Hospitalized Children With Severe Acute Respiratory Infection
13. Wastewater Surveillance Captured an Increase in Adenovirus Circulation in Milan (Italy) during the First Quarter of 2022
14. Long‐term endoscopic surveillance in HBV compensated cirrhotic patients treated with Tenofovir or Entecavir for 11 years.
15. Most patients with advanced cirrhosis treated with bulevirtide monotherapy have a non-monophasic HDV RNA decline patterns: an interim kinetic analysis of real-life setting
16. Comparative performance analysis between manual and automatic RNA extraction to quantify HDV RNA by RoboGene 2.0 kit in untreated and bulevirtide-treated HDV patients
17. Bulevirtide 2 mg/day monotherapy in patients with chronic hepatitis delta with or without cirrhosis: a multicenter european cohort real-life study
18. Safety and effectiveness of up to 3 years’ bulevirtide monotherapy in patients with HDV-related cirrhosis
19. Corrigendum to “Chromosome 3 cluster rs11385942 variant links complement activation with severe COVID-19” [J. Autoimmun. 117C (2020) 102595]
20. Re-emergence of enterovirus D68 in Europe after easing the COVID-19 lockdown, September 2021
21. Prothrombin induced by vitamin K absence or antagonist‐II and alpha foetoprotein to predict development of hepatocellular carcinoma in Caucasian patients with hepatitis C‐related cirrhosis treated with direct‐acting antiviral agents
22. Nasopharyngeal Testing among Healthcare Workers (HCWs) of a Large University Hospital in Milan, Italy during Two Epidemic Waves of COVID-19
23. SAT-199 - Kinetics of hepatitis B core related antigen in patients with compensated HDV cirrhosis treated with Bulevirtide monotherapy for 72 weeks: a single-center study
24. SAT-190 - Quantification of serum HDV RNA in untreated and Bulevirtide-treated patients with CHD: a comparison between Robogene 2.0 and Eurobioplex
25. SAT-181 - Pretreatment and on-therapy HDV RNA levels predict response to Bulevirtide monotherapy in HDV compensated cirrhotic patients treated up to 96 weeks
26. SAT-175 - Significant improvement of non-invasive fibrosis tests in HDV compensated cirrhotic patients with clinically significant portal hypertension treated with BLV monotherapy un to 96 weeks
27. Correlation between HBV core-related antigen and the new quantitative IGG anti-core in treated caucasian HBeAg-negative patients and inactive carriers with and without a functional cure
28. Safety and efficacy of up to 76 weeks 10 mg (high dose) bulevirtide monotherapy in compensated cirrhotics with delta hepatitis
29. Prothrombin induced by vitamin K absence or antagonist‐II and alpha foetoprotein to predict development of hepatocellular carcinoma in Caucasian patients with hepatitis C‐related cirrhosis treated with direct‐acting antiviral agents.
30. SAT440 - Most patients with advanced cirrhosis treated with bulevirtide monotherapy have a non-monophasic HDV RNA decline patterns: an interim kinetic analysis of real-life setting
31. SAT379 - Bulevirtide 2 mg/day monotherapy in patients with chronic hepatitis delta with or without cirrhosis: a multicenter european cohort real-life study
32. SAT381 - Comparative performance analysis between manual and automatic RNA extraction to quantify HDV RNA by RoboGene 2.0 kit in untreated and bulevirtide-treated HDV patients
33. Excellent safety and effectiveness of high-dose myrcludex-B monotherapy administered for 48 weeks in HDV-related compensated cirrhosis: A case report of 3 patients
34. Emergence of divergent enterovirus (EV) D68 sub-clade D1 strains, northern Italy, September to October 2018
35. SAT417 - Safety and efficacy of up to 76 weeks 10 mg (high dose) bulevirtide monotherapy in compensated cirrhotics with delta hepatitis
36. SAT418 - Correlation between HBV core-related antigen and the new quantitative IGG anti-core in treated caucasian HBeAg-negative patients and inactive carriers with and without a functional cure
37. Early Postnatal Infection of Neonates Born to Mothers Infected by SARS-CoV-2 Omicron Variant.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.